Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral Sclerosis
This study provides Class II evidence that serum NfL levels are useful in identifying over 80% of patients with ALS and predicting survival in patients with ALS compared with pTau181 and GFAP levels.
Authors
- Jean‐Paul Cristol (ORCID: https://orcid.org/0000-0001-8563-7278)
- Mehdi Morchikh
- Etienne Mondésert
- Sylvain Lehmann (ORCID: https://orcid.org/0000-0001-6117-562X)
- Christophe Hirtz (ORCID: https://orcid.org/0000-0002-7313-0629)
- Jens Kühle (ORCID: https://orcid.org/0000-0002-6963-8892)
- Elisa De La Cruz (ORCID: https://orcid.org/0000-0003-3345-1628)
- Constance Delaby (ORCID: https://orcid.org/0000-0002-8606-6814)
- Pascal Benkert (ORCID: https://orcid.org/0000-0001-6525-8174)
- Florence Esselin
- Nicolas Pradeilles
- William Camu
- Marie Duchiron
Institutions
- Universitat Autònoma de Barcelona (ES)
- Inserm (FR)
- University of Basel (CH)
- Université de Montpellier (FR)
- Hospital de Sant Pau (ES)
- University Hospital of Basel (CH)
- Hôpital Gui de Chauliac (FR)
- Hôpital Lapeyronie (FR)
Publication Details
- Journal
- Neurology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1212/wnl.0000000000213400
- Citations
- 12
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 16.67
Funders
- Fondation pour la Recherche Médicale